Aiming to identify parameters that could affect disease outcome, univariate analysis of PFS was performed by evaluating patients’ age, sex, frailty score, ECOG, ISS, LDH, β2-microglobulin, cytogenetics, creatinine clearance, high-grade anemia, high-grade neutropenia, bone lesions, G-CSF and EPO use, the deepness of response, treatment delay and reduction. This evidence concerns the gene HLA-G and neutropenia.